MyMD Pharmaceuticals Enrolls First Person in Stage 2 Scientific Test of MYMD-1 as a Therapy for Delaying Aging as well as Expanding Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Company”), a scientific phase pharmaceutical company committed to extending healthy life-span, today revealed that the very first person has been registered in the Business’s Phase 2 medical trial of lead candidate MYMD-1, an oral immune regulator medication, as a therapy for delaying aging and broadening healthy and balanced life expectancy.

The main endpoint for the Stage 2 double-blind, placebo-controlled professional test is to accomplish a reduction in the circulating degrees of (TNF-α), lump necrosis aspect receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that create inflammation and help turn on the process of aging. The second measures of the trial will certainly be the security, tolerability, and pharmacokinetics in this populace of people.

” In a Stage 1 clinical test of MYMD-1, we showed the medication’s statistically considerable efficiency in reducing levels of TNF-α, a key player in creating pathological aging, in the blood. The FDA has actually accepted TNF-α decrease as the primary endpoint for our Phase 2 research study, which our company believe placements us well for a successful Phase 2 result,” claimed Chris Chapman, M.D., Head Of State, Supervisor and also Chief Medical Officer of MyMD. “The initiation of client enrollment in this research study developments our mission to reduce the aging process, avoid loss of muscle tissue in aging, limitation frailty, and also extend healthy and balanced life expectancy.”

MyMD has stated that there are no FDA-approved medications for treating aging disorders and also extending healthy and balanced life expectancy humans, a market anticipated to be at least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most proposed drugs by revenue, an international market of roughly $40 billion annually,2 and, according to Nature Aging journal,3 a slowdown in maturing that would increase life span by one year is worth $38 trillion as well as by one decade deserves $367 trillion.

Along with aging, MYMD-1’s unique activity in controling the body immune system and dealing with persistent inflammation is being developed for the treatment of autoimmune disease, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, and also inflammatory bowel illness.

” We mean to begin creating procedures for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising frequency of rheumatoid arthritis and also various other autoimmune and inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, as well as we believe our by mouth carried out medicine with extremely reduced poisoning would certainly be turbulent to the $60 billion market for RA if accepted by the FDA for this sign.”

Rheumatoid joint inflammation impacts roughly 40 million individuals around the world.4.

Regarding MYMD-1.

Originally developed for autoimmune diseases, MYMD-1’s primary function is to reduce the aging process, stop sarcopenia and also frailty, and extend healthy lifespan. Because it can cross the blood-brain barrier and get to the main nervous system (CNS), MYMD-1 is likewise positioned to be a possible therapy for brain-related disorders. Its system of activity and also efficacy in diseases consisting of multiple sclerosis (MS) as well as thyroiditis have actually been researched via partnerships with several scholastic institutions. MYMD-1 is also showing assurance in pre-clinical studies as a prospective treatment for article- COVID-19 problems and as an anti-fibrotic and anti-proliferation healing.

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by doing as a discerning inhibitor of growth necrosis factor-alpha (TNF-α), a chauffeur of chronic swelling. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical studies to selectively block TNF-α when it comes to be overactivated in autoimmune diseases and also cytokine tornados, but not block it from doing its normal work of being a first responder to any regular kind of modest infection. MYMD-1’s ease of dental dosing is an additional differentiator compared to presently available TNF-α blockers, all of which call for distribution by shot or mixture. No accepted TNF prevention has ever been dosed by mouth. Additionally, the medication is not immunosuppressive and also has actually not been revealed to trigger the serious negative effects common with typical therapies that deal with swelling.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical company dedicated to expanding healthy lifespan, is focused on creating 2 novel healing platforms that treat the sources of illness instead of only resolving the signs and symptoms. MYMD-1 is a drug system based upon a professional stage little molecule that controls the immune system to manage TNF-α, which drives persistent inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, boost longevity, as well as deal with autoimmune illness as well as COVID-19- connected clinical depression. The Business’s second medicine platform, Supera-CBD, is being created to deal with chronic pain, dependency and epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and is being created to address as well as improve upon the quickly expanding CBD market, that includes both FDA approved medications as well as CBD items not currently regulated as medicines. For more details, go to www.mymd.com.